One misread study didn't just change prescribing — it assembled a new structure: fear in the headlines, caution in the guidelines, a generation of clinicians trained without knowledge, and twenty years of women without options. Every step produced the next. That's not a mistake. That's a high assembly index.
This is the force that started the crisis — and the one that took longest to correct it. In July 2002, the Women's Health Initiative published preliminary results. The headlines got the science wrong. Doctors stopped prescribing. Women were left without treatment. What followed was twenty years of fear encoded into clinical practice — until the evidence finally forced its way back.
The WHI used one specific formulation in women averaging 63 years old — over a decade past menopause onset. The cardiovascular risks it found didn't apply to women in their 40s or 50s initiating treatment at perimenopause. That distinction was in the study. It was not in the coverage. Medical schools stopped teaching HRT. A generation of clinicians assembled their practice around fear that outlasted the science.
The study's actual finding: In a population of women averaging 63 years old, one formulation of HRT was associated with a small increase in certain risks. This was reported as: "HRT causes breast cancer and heart disease." The distinction between those two statements was the first step in assembling twenty years of inadequate care.
For eleven years, no new treatments were approved. Women were offered antidepressants — often off-label, often without explanation. Europe and Australia kept prescribing. The US stayed frozen. Women who couldn't get answers from clinicians found each other online instead — which is where the community force begins.
By 2012, follow-up research had corrected the record. NAMS updated its guidelines supporting HRT for healthy women within ten years of menopause onset. The FDA's black-box warning stayed up until November 2025. Prescribers who stopped in 2002 stayed stopped — not because the evidence required it, but because fear, once encoded into training culture, is slow to leave.
Estimated US prescriptions · millions · before and after WHI panic
Indexed to 2000 = 100 · showing the collapse, the floor, and the slow recovery arc
Relative to pre-WHI peak (28M/yr) — the gap is still open 22 years later
A single misread study in 2002 triggered a 73% drop in prescriptions within a few years. That isn't a market correction — it's a medical system that abandoned patients based on headline coverage of preliminary data. The recovery has been painfully slow: after 14 years, only 37% of lost prescriptions have come back. Most women who needed treatment between 2003 and 2017 didn't get it. That's not a statistic. That's a generation.
Significant approvals by era — from early HRT to non-hormonal options
Number of FDA-approved menopause treatment categories available · cumulative
HRT prescriptions dropped 65% after 2002 WHI publication; slow recovery from 2013
Drug approvals for menopause nearly stopped after 2002 and didn't meaningfully resume until 2023, when fezolinetant (Veozah) became the first non-hormonal treatment approved in two decades. The treatment option count stayed flat for over 15 years — not because the science was settled, but because there was no commercial incentive to pursue it. The FDA black box warning wasn't removed until November 2025, 23 years after it went up.
At the trough, 20.5 million fewer prescriptions were written per year than before 2002. Over the following decade, that adds up to over 200 million missed treatment-years. The partial recovery since 2013 is real — but the gap is still open. And it took a community of 750,000 women, $1.8 billion in VC, and a formal NASEM report to get the medical system to revisit what a single 2002 headline had locked in.